Neuroplastogen Programs
Major Depressive Disorder / Treatment-Resistant Depression
Key Facts
About Delix Therapeutics
Delix Therapeutics is a private, preclinical-stage biotech company developing a new generation of brain health medicines. Its core technology platform centers on neuroplastogens—small molecules designed to promote selective neuroplasticity and rewire neural circuits without the hallucinogenic effects or safety concerns of classic psychedelics. The company is targeting major neuropsychiatric disorders with a pipeline of novel compounds, positioning itself at the forefront of a potential paradigm shift in neuroscience. Backed by investors and led by a team experienced in neuroscience and drug development, Delix seeks to address the vast unmet need in mental health with scalable, non-hallucinogenic therapeutics.
View full company profileAbout Delix Therapeutics
Delix Therapeutics is a private, preclinical-stage biotech company developing a new generation of brain health medicines. Its core technology platform centers on neuroplastogens—small molecules designed to promote selective neuroplasticity and rewire neural circuits without the hallucinogenic effects or safety concerns of classic psychedelics. The company is targeting major neuropsychiatric disorders with a pipeline of novel compounds, positioning itself at the forefront of a potential paradigm shift in neuroscience. Backed by investors and led by a team experienced in neuroscience and drug development, Delix seeks to address the vast unmet need in mental health with scalable, non-hallucinogenic therapeutics.
View full company profileAbout Delix Therapeutics
Delix Therapeutics is a private, preclinical-stage biotech company developing a new generation of brain health medicines. Its core technology platform centers on neuroplastogens—small molecules designed to promote selective neuroplasticity and rewire neural circuits without the hallucinogenic effects or safety concerns of classic psychedelics. The company is targeting major neuropsychiatric disorders with a pipeline of novel compounds, positioning itself at the forefront of a potential paradigm shift in neuroscience. Backed by investors and led by a team experienced in neuroscience and drug development, Delix seeks to address the vast unmet need in mental health with scalable, non-hallucinogenic therapeutics.
View full company profile